TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma

NCT06485466 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

101

Enrollment

OTHER

Sponsor class

Conditions

Unresectable Hepatocellular Carcinoma
Transarterial Chemoembolization
Camrelizumab
Apatinib

Interventions

COMBINATION_PRODUCT: TACE plus camrelizumab and apatinib
COMBINATION_PRODUCT: Camrelizumab and apatinib

Sponsor

Guohui Xu